MedTrace Logo

Swiss HCVree Trial

NCT02785666 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2018-08-31

No results posted yet for this study

Summary

The investigators aim at investigating the efficacy of grazoprevir/elbasvir ±ribavirin in HIV-positive MSM participating in the SHCS in a broader setting of coinfected MSM. The study pursues a comprehensive approach of a treat, counsel and cure strategy exploring the impact of such a strategy in a representative HIV/HCV-coinfected MSM population. This study is a nested project of the Swiss HIV Cohort Study entitled "The Swiss HCVree Trial".

Conditions

  • Hepatitis C
  • HIV

Interventions

DRUG

grazoprevir/elbasvir, ribavirin

To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection

BEHAVIORAL

Behavioural Intervention

To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Dominique L Braun, MD · University Hospital Zurich, University of Zurich

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-04-30
Completion
2018-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785666 on ClinicalTrials.gov